NOVAVAX INC Stock Split Ratio
NOVAVAX INC (NVAX) reported Stock Split Ratio of 5.00% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2022-03-01
- NOVAVAX INC stockholders' equity note, stock split, conversion ratio for fiscal 2021 was 5.00%, a 0.00% change from fiscal 2020.
- NOVAVAX INC stockholders' equity note, stock split, conversion ratio for fiscal 2020 was 5.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|
| 2021-12-31 | 5.00% 10-K · filed 2022-03-01 | |
| 2020-12-31 | 5.00% 10-K · filed 2021-03-01 | |
| 2019-05-10 | 2000.00% 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |